EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark NOVELLUS was filed as Word mark on 01/04/2019 at the European Union Intellectual Property Office.
It was registered as a trademark on 06/13/2019.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 018006607 |
| Application date | January 4, 2019 |
| Publication date | March 6, 2019 |
| Entry date | June 13, 2019 |
| Expiration date | January 4, 2029 |
Trademark owner
1035 Cambridge Street, Suite 17B
02141 Cambridge
US
02141 Cambridge
US
Trademark representatives
C/Bilbao, 1, 5º
03001 Alicante
ES
goods and services
5
Pharmaceuticals; Gene therapy preparations, tests or reagents; chemical reagents for medical and veterinary purposes; Gene therapy preparations, tests or reagents, that apply gene-editing technology that uses de novo-engineered gene-editing proteins expressed with synthetic messenger ribonucleic acid; synthetic messenger ribonucleic acid preparations for medical and veterinary purposes and related chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; synthetic ribonucleic acid preparations, tests or reagents encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator like effector nucleases for in vivo and in vitro genetic engineering; Cell therapy preparations, tests or reagents; Cell therapy preparations, tests or reagents, that use cell reprogramming technology that uses reprogramming factors expressed with synthetic messenger ribonucleic acid; synthetic messenger ribonucleic acid preparations for medical and veterinary purposes and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic ribonucleic acid preparations, tests or reagents encoding reprogramming factors; pharmaceutical products for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing
42
Pharmaceutical research and development services; Pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without messenger ribonucleic acid engineering; Pharmaceutical research and development services, namely, gene-editing services, messenger ribonucleic acid engineering services, cell reprogramming services, and cell therapy development services; scientific laboratory services, namely, stem cell production services; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services, namely, gene-editing services
ID: 11018006607